Literature DB >> 2011645

Regular hypnotic drug treatment in a sample of 32,679 Swedes: associations with somatic and mental health, inpatient psychiatric diagnoses and suicide, derived with automated record-linkage.

C Allgulander1, P Näsman.   

Abstract

We studied Swedish survey responders who reported regular treatment with hypnotic drugs, to find associations to perceived health problems, inpatient psychiatric diagnoses, and subsequent suicide. Among 32,679 sampled Swedes, 26,952 (83%) participated, 500 of which (2%) reported regular hypnotic drug treatment. The rate of treatment was higher in women, and increased by age in both sexes. The major findings were high odds of concurrent psychoactive drug treatments, nervous symptoms and insomnia, as well as high rates of circulatory and musculoskeletal conditions in both sexes, with indicators of disability and sleep-disturbing symptoms. During a 15-year period, 35% of the men and 21% of the women who reported regular hypnotic drug treatment had also been admitted to inpatient psychiatric care. Substance abuse was diagnosed in 20% of the men and 4.3% of the women reporting hypnotic drug treatment. In multiple logistic regression models, the highest odds for regular hypnotic drug treatment were incurred by recent/current insomnia, nervous symptoms, and other psychoactive drug treatment. We conclude that therapy was principally given according to some current peer guidelines. Yet, further research is needed into the risk/benefit ratio of sustained hypnotic drug therapy in patients with qualifying somatic and psychiatric disorders to obtain a more uniformly based consensus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2011645     DOI: 10.1097/00006842-199101000-00009

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  8 in total

Review 1.  Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA.

Authors:  W Vaughn McCall; Ruth M Benca; Peter B Rosenquist; Mary Anne Riley; Laryssa McCloud; Jill C Newman; Doug Case; Meredith Rumble; Andrew D Krystal
Journal:  Am J Psychiatry       Date:  2016-09-09       Impact factor: 18.112

2.  Mortality Following Nonfatal Opioid and Sedative/Hypnotic Drug Overdose.

Authors:  Sidra Goldman-Mellor; Mark Olfson; Cristina Lidon-Moyano; Michael Schoenbaum
Journal:  Am J Prev Med       Date:  2020-05-07       Impact factor: 5.043

Review 3.  Women in clinical drug trials. An update.

Authors:  D L Schmucker; M S O'Mahony; E S Vesell
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

4.  Prescription Medications for the Treatment of Insomnia and Risk of Suicide Attempt: a Comparative Safety Study.

Authors:  Jill E Lavigne; Kwan Hur; Cathleen Kane; Anthony Au; Todd M Bishop; Wilfred R Pigeon
Journal:  J Gen Intern Med       Date:  2019-06-03       Impact factor: 5.128

5.  Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs.

Authors:  Børge Sivertsen; Siri Omvik; Ståle Pallesen; Inger Hilde Nordhus; Bjørn Bjorvatn
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

Review 6.  Pharmacotherapy of insomnia: practice and prospects.

Authors:  J Dingemanse
Journal:  Pharm World Sci       Date:  1995-05-26

Review 7.  Gender differences in pharmacokinetics.

Authors:  C H Gleiter; U Gundert-Remy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

8.  Greater incidence of depression with hypnotic use than with placebo.

Authors:  Daniel F Kripke
Journal:  BMC Psychiatry       Date:  2007-08-21       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.